Goodwin Paris advised Biomunex Pharmaceuticals, a biopharmaceutical company with operations in Paris (France) and Cambridge (MA, USA), on its exclusive global licensing agreement with Ipsen for the BMX-502 program. BMX-502, a MAIT cell activator (also known as a "MAIT engager"), represents a new therapeutic class in immuno-oncology.
Ipsen, a global biopharmaceutical leader, focuses on developing innovative treatments in three therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Through this agreement, Ipsen has secured exclusive worldwide rights to develop, manufacture, and commercialize BMX-502, a novel T cell engager (TCE) currently in preclinical development with first-in-class potential.
BMX-502 is a bispecific antibody designed to target MAIT cells—an unconventional subset of T cells—along with the clinically validated tumor antigen GPC3, to selectively destroy cancer cells.
The Goodwin team advising Biomunex was led by Marie Fillon, and included Susan Lee and Lucy Sharpleson regulatory aspects, Gretchen Scott and Joseph Ndep on RGPD compliance aspects, and Louis de Chezelles.